<DOC>
	<DOCNO>NCT01335711</DOCNO>
	<brief_summary>To explore effect early viral kinetics viral load , determine safety , tolerability anti-viral response plasmid DNA vaccine CHRONVAC-C administer i.m . combination electroporation follow standard care ( SOC ) treatment naïve chronic HCV genotype 1 patient .</brief_summary>
	<brief_title>CHRONVAC-C Study Followed Standard Care Chronic Hepatitis C Virus ( HCV ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Male female subject 18 65 year age know chronic hepatitis C infection , treatment naїve ( earlier treat HCV infection ) plan start standard care within 12 week screen . Known genotype 1 infection . Viral load equal 1000 IU/ml BMI less 35 . Considered probable deltoid muscle ( left right ) subject reach vaccination use 12.7 mm cannula injection 15 mm applicator tip electroporation . Written inform consent obtain , copy provide subject . Subject legally competent able communicate effectively study personnel . Subject likely cooperate attend clinic appoint time study Subject clinically significant concomitant disease HCV medical history discretion investigator . Subject clinically significant finding physical examination , vital sign , ECG clinical laboratory evaluation discretion investigator . Subject clinical biochemical sign cirrhosis . Positive hepatitis B surface antigen ( HBsAg ) . Positive HIV antigen antibody test . Subject ongoing and/or know viral infection HCV require treatment and/or special medical intention . Subject receive previous treatment HCV . Radiation therapy cytotoxic chemotherapeutic agent within 4 week prior first dose study drug . Treatment immunomodulating agent systemic corticosteroid , IL2 , IFNalpha , IFNbeta , IFNgamma within 4 week prior first dose study drug . ( Corticosteroid nasal spray , inhaled steroid asthma and/or topical steroid allow , however vaccination area . ) Immunization within 30 day first dose study drug . Subject receive investigational drug product , enrol investigational drug protocol within period 30 day prior receive first dose study drug . Prior treatment DNA therapy . Known allergy towards vaccine . Known allergy contraindication interferon and/or ribavirin excipients Known abuse alcohol , drug pharmaceutical . History , sign symptoms cardiac disease . Presence implantable pacemaker . Any metal implant within treatment area ( close right and/or leave deltoid muscle ) . Diagnoses serious psychiatric illness may influence study participation . Female subject pregnant breast feeding . Female subject clinically sterile ( hysterectomy , tubal ligation postmenopausal ( amenorrhea &gt; 1 year FSH &gt; 30 mU/ml ) OR clinically sterile unwilling use reliable contraception method . Female subject positive urine pregnancy test . Male subject unwilling use condom active prevention pregnancy first vaccination 4 month last injection . Subject immediate family investigator site personnel directly affiliate study . Immediate family define spouse , parent , child sibling , whether biologically legally adopt .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>